<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189878</url>
  </required_header>
  <id_info>
    <org_study_id>MREC/03/4/003</org_study_id>
    <secondary_id>MF 8000/12375</secondary_id>
    <nct_id>NCT00189878</nct_id>
  </id_info>
  <brief_title>A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria</brief_title>
  <official_title>Multi-centre Prospective Randomised Double-blind Placebo-controlled Study of Methotrexate in the Treatment of Chronic Idiopathic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnsley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barnsley Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether methotrexate produces significant
      improvement in chronic idiopathic urticaria, compared with placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic idiopathic urticaria is thought to affect approximately 0.1% of the population. It
      can be very disabling and difficult to treat. Antihistamines are the only drugs licensed for
      treatment of urticaria, however there is a group of severely affected patients with chronic
      idiopathic urticaria who fail to respond. Previous trials have shown ciclosporin to be
      beneficial, and small studies support the use of intravenous immunoglobulins and
      plasmapheresis. However, not only are these options expensive, but since chronic idiopathic
      urticaria may persist for years, their prolonged use may be limited by adverse effects. We
      have previously published a report of 2 patients who responded to methotrexate, and wish to
      properly evaluate the efficacy of methotrexate in the treatment of CIU.

      In the first part of the study patients will be given either placebo or methotrexate for 8
      weeks and in the second part of the study, non-responders will be offered open labelled
      methotrexate for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to recruit
  </why_stopped>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A positive response to treatment (a reduction to &lt;25% of baseline urticaria activity scores)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>1 methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>given placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (drug)</intervention_name>
    <description>Methotrexate 10 to 15 mg weekly for 8 weeks</description>
    <arm_group_label>1 methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo capsules</intervention_name>
    <description>4-6 placebo capsules - identical to capsules containing methotrexate</description>
    <arm_group_label>2 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe unremitting chronic idiopathic urticaria

          -  disease resistant to treatment with antihistamines

          -  aged 18 years or more

        Exclusion Criteria:

          -  predominant physical urticaria

          -  urticarial vasculitis

          -  any contraindication to the use of methotrexate, eg. pregnancy / breast feeding, women
             wanting to conceive or man wanting to father a child within 12 months of entry, use of
             drugs which interact, underlying medical conditions

          -  use of immunosuppressant within 4 weeks of entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth A Sabroe, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnsley Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <name_title>Jeffrey Bailey</name_title>
    <organization>Research and Development, Barnsley Hospital NHS Foundation Trust</organization>
  </responsible_party>
  <keyword>chronic idiopathic urticaria</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

